Clinical trials have shown that anti-VEGF treatment creates a window for tumor vascular normalization, thereby increasing the recruitment of immune cells into the tumor immune microenvironment and enhancing the tumor-killing capabilities of these cells [43]. The gene discussed is VEGFA; the disease is neoplasm.